About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Current Hematologic Malignancy Reports
›
Top Articles
Current Hematologic Malignancy Reports
Hematology
,
Oncology
4.4
(top 3%)
Impact Factor
5
(top 3%)
extended IF
40
(top 10%)
H-Index
405
authors
750
papers
8.9K
citations
1.6K
citing journals
8.5K
citing authors
Most Cited Articles of Current Hematologic Malignancy Reports
Title
Year
Citations
Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies
2013
177
Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases
2016
94
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
2016
86
Incidence and Burden of the Myelodysplastic Syndromes
2015
82
Bruton's tyrosine kinase (BTK) inhibitors in clinical trials
2014
80
Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update
2016
75
New proteasome inhibitors in myeloma
2012
74
Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials
2013
68
Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer
2016
67
Targeting BTK in CLL: Beyond Ibrutinib
2019
65
Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors
2012
63
Role of Microenvironment in Resistance to Therapy in AML
2015
62
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
2018
62
The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis
2009
60
Breast implant-associated anaplastic large cell lymphoma: a systematic review of the literature and mini-meta analysis
2013
57
Immunological Consequences of JAK Inhibition: Friend or Foe?
2015
56
Primary CNS lymphoma
2014
55
CD30+ neoplasms of the skin
2011
55
Clinical implications of c-Kit mutations in acute myelogenous leukemia
2009
55
Emerging EZH2 Inhibitors and Their Application in Lymphoma
2018
53
An immune dysregulation in MPN
2014
53
Targeting the microenvironment in acute myeloid leukemia
2015
52
Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes
2012
52
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You
2016
50
Early Palliative Care for Patients with Hematologic Malignancies: Is It Really so Difficult to Achieve?
2017
49
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.